Levetiracetam (Epilepsy) updated on 04-22-2025

ADHD (Attention deficit hyperactivity disorder): Diagnosis/Risk

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S17431
R73237
Madley-Dowd_SE (Levetiracetam) (Controls exposed to LTG), 2024 Attention Deficit Hyperactivity Disorder - ICD-8/9/10 codes and/or ADHD medication prescription - Mean 5-20 years old (according groups) during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No Partial overlapping 0.54 [0.31;0.95] C
excluded (control group)
14/556   109/2,383 123 556
ref
S17432
R73238
Madley-Dowd_SE (Levetiracetam) (Controls unexposed, sick), 2024 Attention Deficit Hyperactivity Disorder - ICD-8/9/10 codes and/or ADHD medication prescription - Mean 5-20 years old (according groups) during pregnancy (anytime or not specified) population based cohort retrospective unexposed, sick Adjustment: Yes Partial overlapping 0.99 [0.58;1.68] 190/556   929/10,769 1,119 556
ref
S17252
R72261
Madley-Dowd_UK (Levetiracetam) (Epilepsy), 2024 Attention Deficit Hyperactivity Disorder - ICD10 codes and/or ADHD medication prescription - Median 4.19 (2.56-6.79) years old during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed, sick Adjustment: Yes 1.23 [0.16;9.58] -/174   38/4,075 - 174
ref
S15871
R65402
Dreier (Levetiracetam) (Epilepsy) (Controls exposed to LTG), 2023 Attention-deficit/hyperactivity disorder (ADHD) - Corresponding ICD-10 F-chapter - Up to 22 years of age during pregnancy (anytime or not specified) population based cohort propective exposed to other treatment, sick excluded Adjustment: No 0.73 [0.42;1.29] C
excluded (control group)
14/1,061   95/5,288 109 1,061
ref
S15872
R65410
Dreier (Levetiracetam) (Epilepsy) (Controls unexposed, sick), 2023 Attention-deficit/hyperactivity disorder (ADHD) - Corresponding ICD-10 F-chapter - Up to 22 years of age during pregnancy (anytime or not specified) population based cohort propective unexposed, sick Adjustment: Yes 1.78 [1.03;3.07] 14/1,061   528/22,203 542 1,061
ref
S7511
R46410
Huber-Mollema (Levetiracetam), 2019 Diagnosis of ADHD throughout pregnancy prospective cohort exposed to other treatment, sick Adjustment: No 0.25 [0.01;4.74] C 0/30   5/88 5 30
ref
S7308
R46411
Bromley (Levetiracetam), 2016 Maladaptive behavior: Attention (BASC) (5-9 years old) during pregnancy (anytime or not specified) retrospective cohort (registry) unexposed, sick Adjustment: No extrapolated (cont. endpoint) 0.86 [0.41;1.78] -/42   -/55 - 42
ref
Total 5 studies 1.17 [0.82;1.68] 1,666 1,863
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Madley-Dowd_SE (Levetiracetam) (Controls unexposed, sick), 2024Madley-Dowd_SE, 2024 1 0.99[0.58; 1.68]1,11955638%ROB confusion: moderateROB selection: lowROB classification: lowROB missing: lowROB mesure: moderateROB reporting: moderate Madley-Dowd_UK (Levetiracetam) (Epilepsy), 2024Madley-Dowd_UK, 2024 2 1.23[0.16; 9.58]-1743%ROB confusion: moderateROB selection: lowROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Dreier (Levetiracetam) (Epilepsy) (Controls unexposed, sick), 2023Dreier, 2023 3 1.78[1.03; 3.07]5421,06136%ROB confusion: seriousROB selection: lowROB classification: moderateROB missing: lowROB mesure: criticalROB reporting: moderate Huber-Mollema (Levetiracetam), 2019Huber-Mollema, 2019 4 0.25[0.01; 4.74]5302%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: criticalROB mesure: moderateROB reporting: moderate Bromley (Levetiracetam), 2016Bromley, 2016 5 0.86[0.41; 1.78]-4222%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (5 studies) I2 = 8% 1.17[0.82; 1.68]1,6661,8630.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Levetiracetam) (Controls unexposed, sick; 2: Levetiracetam) (Epilepsy; 3: Levetiracetam) (Epilepsy) (Controls unexposed, sick; 4: Levetiracetam; 5: Levetiracetam;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.17[0.82; 1.68]1,6661,8638%NAMadley-Dowd_SE (Levetiracetam) (Controls unexposed, sick), 2024 Madley-Dowd_UK (Levetiracetam) (Epilepsy), 2024 Dreier (Levetiracetam) (Epilepsy) (Controls unexposed, sick), 2023 Huber-Mollema (Levetiracetam), 2019 Bromley (Levetiracetam), 2016 5 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 1.20[0.84; 1.71]1,6611,8339%NAMadley-Dowd_SE (Levetiracetam) (Controls unexposed, sick), 2024 Madley-Dowd_UK (Levetiracetam) (Epilepsy), 2024 Dreier (Levetiracetam) (Epilepsy) (Controls unexposed, sick), 2023 Bromley (Levetiracetam), 2016 4 exposed to other treatment, sickexposed to other treatment, sick 0.25[0.01; 4.74]530 -NAHuber-Mollema (Levetiracetam), 2019 1 Tags Adjustment   - No  - No 0.80[0.39; 1.63]5720%NAHuber-Mollema (Levetiracetam), 2019 Bromley (Levetiracetam), 2016 2   - Yes  - Yes 1.32[0.87; 2.00]1,6611,79112%NAMadley-Dowd_SE (Levetiracetam) (Controls unexposed, sick), 2024 Madley-Dowd_UK (Levetiracetam) (Epilepsy), 2024 Dreier (Levetiracetam) (Epilepsy) (Controls unexposed, sick), 2023 3 extrapolated (cont. endpoint)extrapolated (cont. endpoint) 0.86[0.41; 1.79]-42 -NABromley (Levetiracetam), 2016 1 Partial overlappingPartial overlapping 0.99[0.58; 1.68]1,119556 -NAMadley-Dowd_SE (Levetiracetam) (Controls unexposed, sick), 2024 1 All studiesAll studies 1.17[0.82; 1.68]1,6661,8638%NAMadley-Dowd_SE (Levetiracetam) (Controls unexposed, sick), 2024 Madley-Dowd_UK (Levetiracetam) (Epilepsy), 2024 Dreier (Levetiracetam) (Epilepsy) (Controls unexposed, sick), 2023 Huber-Mollema (Levetiracetam), 2019 Bromley (Levetiracetam), 2016 50.15.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-3.53.71.7910.000Madley-Dowd_SE (Levetiracetam) (Controls unexposed, sick), 2024Madley-Dowd_UK (Levetiracetam) (Epilepsy), 2024Dreier (Levetiracetam) (Epilepsy) (Controls unexposed, sick), 2023Huber-Mollema (Levetiracetam), 2019Bromley (Levetiracetam), 2016

Asymetry test p-value = 0.4523 (by Egger's regression)

slope=0.4506 (0.3778); intercept=-0.8608 (0.9992); t=0.8615; p=0.4523

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 15871, 17431

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 1.20[0.84; 1.71]1,6901,8339%NAMadley-Dowd_SE (Levetiracetam) (Controls unexposed, sick), 2024 Madley-Dowd_UK (Levetiracetam) (Epilepsy), 2024 Dreier (Levetiracetam) (Epilepsy) (Controls unexposed, sick), 2023 Bromley (Levetiracetam), 2016 4 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.62[0.42; 0.92]2371,6470%NAMadley-Dowd_SE (Levetiracetam) (Controls exposed to LTG), 2024 Dreier (Levetiracetam) (Epilepsy) (Controls exposed to LTG), 2023 Huber-Mollema (Levetiracetam), 2019 30.510.01.0